Director Michael Vasconcelles filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of stock options and restricted stock units in MacroGenics Inc on October 30, 2026.

Key Highlights

  • Reporting person: Michael Vasconcelles, identified as a Director of MacroGenics Inc (NASDAQ:MGNX).
  • Stock options granted: 44,000 stock options (right to buy) with an exercise price of $2.40, granted on October 30, 2026, expiring October 30, 2036.
  • RSUs granted: 7,500 restricted stock units acquired on October 30, 2026, each representing a contingent right to receive one share of common stock.
  • Option vesting: Options vest in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the grant date.
  • RSU vesting: RSUs vest as to 33% of the total shares one year after the grant date and 33% each year thereafter.
  • Price paid: Both the options and the RSUs were acquired at a price of $0, according to the filing.
  • Post-transaction holdings: Vasconcelles beneficially owns 44,000 options and 7,500 RSUs directly following these transactions.

MacroGenics Director Vasconcelles Receives Equity Awards in October 2026

According to the Form 4 filed on November 3, 2026, Michael Vasconcelles, a director of MacroGenics Inc (NASDAQ:MGNX), reported the acquisition of two derivative securities on October 30, 2026. The filing covers transactions in Table II, covering derivative securities, with no non-derivative (Table I) transactions reported.

The filing discloses that Vasconcelles received a stock option granting the right to buy 44,000 shares of MacroGenics common stock at an exercise price of $2.40 per share. The option has a ten-year term, expiring October 30, 2036. Per the filing's explanation of responses, "the option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant." Both the option grant and the RSU award are held directly and were acquired at a reported price of $0.

In addition, the filing reports that Vasconcelles acquired 7,500 restricted stock units on the same date. Each RSU represents a contingent right to receive one share of the issuer's common stock. According to the filing, the RSUs "will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter." Following both transactions, Vasconcelles beneficially owns 44,000 options and 7,500 RSUs directly. The Form 4 was signed by Beth A. Smith as attorney-in-fact on November 3, 2026.

What Was Disclosed

MacroGenics director Michael Vasconcelles disclosed the acquisition of 44,000 stock options at $2.40 per share and 7,500 restricted stock units on October 30, 2026, both obtained at $0 cost and subject to multi-year vesting schedules.